# KEYNOTE-799 (NCT03631784)

> A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03631784
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-small Cell Lung Cancer
- Interventions: Pembrolizumab 200 mg; Paclitaxel 45 mg/m^2; Carboplatin AUC6; Cisplatin 75 mg/m^2; Pemetrexed 500 mg/m^2; Thoracic Radiation Therapy (TRT); Paclitaxel 200 mg/m^2; Carboplatin AUC2
- Enrollment: 216
- Primary outcome: Percentage of Participants Who Developed Grade 3 or Higher Pneumonitis
- Primary outcome: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

## Commentary we found

- X threads: 8
- YouTube: 5
- Podcasts: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-799-nct03631784

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03631784", "email": "<work email>"}; the inbox owner confirms by the emailed link.